Effect of intracoronary tirofiban in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction
10.3760/cma.j.issn.1673-4904.2009.19.009
- VernacularTitle:急性心肌梗死急诊介入治疗中替罗非班冠状动脉内注入对疗效的影响
- Author:
Jing LIU
;
He SONG
;
Yuanzhe JIN
;
Qi WANG
;
Donghui ZHOU
- Publication Type:Journal Article
- Keywords:
Acute myocardial infarction;
Angioplasty,transluminal,percutaneous coronary;
Tirofiban;
Myocardial reperfusion
- From:
Chinese Journal of Postgraduates of Medicine
2009;32(19):19-21
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of intracoronary tirofiban during percutaneous coronary intervention(PCI)for patients with acute myocardial infarction(AMI).Methods Seventy-six consecutive AMI patients,treated with primary coronary angioplasty in 12 hours were enrolled.They were randomly divided into two groups:tirofiban group(39 cases)and control group(37 cases).Tirofiban group was treated with intracoronary timfiban during PCI and after the operation for 48 hours.Both of them were given heparin in PCI and aspirin,clopidogrel before PCI.At the end of PCI procedure,angiographic features such as TIMI flow grade and TIMI myocardial perfusion grade(TMPG)were analyzed.The difference of two groups in complication and major adverse cardiac events(MACE) was investigated.Results The myocardial reperfusion of tirofiban group was better than that of control group[TIMI grade 3 flow 94.9%(37/39) vs 78.4%(29/37),P<0.05;TMPG 3 grade 89.7%(35/39)vs 67.6%(25/37),P<0.05].There was no significant difference between two groups in bleeding complication.The occurrence of MACE in tirofiban group was less than that in control group[7.7%(3/39)vs 18.9%(7/37),P<0.05].Conclusion Intracoronary tirofiban dunng primary PCI in patients with AMI can improve coronary flow and myocardial perfusion,and has no more bleeding and less MACE occurrence.
